Clinical Trial Update: PTG-300 in Subjects With Hereditary Hemochromatosis [Phase 2]

View source ↗

Summary

Phase 2 study of PTG-300 for hereditary hemochromatosis has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Hemochromatosis

Drugs mentioned

• PTG-300

Snippet

Sponsor: Protagonist Therapeutics, Inc. | Conditions: Hereditary Hemochromatosis | Phase 2 | Status: COMPLETED | Results posted: 2023-06-15